Last reviewed · How we verify
NCT04376008
A Prospective Study Of Free-Hand Transperineal Image Fusion Targeted Biopsies Under Local Anesthesia
NA trial testing Standard prostate biopsy in Prostate Neoplasm in 1,050 participants. Completed in 1 June 2022.
1 May 2021
Quick facts
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 1,050 |
| Start date | 1 May 2018 |
| Primary completion | 1 May 2021 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Standard prostate biopsy
- Targeted and standard prostate biopsy
Conditions studied
- Prostate Neoplasm — all drugs for Prostate Neoplasm →
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Who can join
Adults 18 to 80, male only, with Prostate Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial aims to prospectively assess the feasibility, complications and functional results of free-hand transperineal image fusion targeted biopsies under local anesthesia in a large group of patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04376008
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Neoplasm
Currently open trials in the same condition.
- NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
- NCT05710380 — MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy · NA · recruiting
- NCT06292897 — Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression · recruiting
- NCT04045717 — Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 · Phase 2 · active not recruiting
- NCT04075305 — The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study · recruiting
Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials
Trials by the same sponsor.
- NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
- NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
- NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04376008 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Last refreshed: 24 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04376008.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing